

DOCKET NO.: RTS-0339

"Express Mail" Label No.: EV053177089US

Date of Deposit: 12/14/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kenneth W. Dobie et al.

Serial No.: Not yet assigned

Group No.: Not yet assigned

Filed: herewith

For: Antisense Modulation of CD36L1 Expression

#3 / K.T.
3/13
I.D.S.



BOX SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: December 14, 2001


Respectfully submitted,

Donna T. Ward

Registration No. 48,271

ISIS PHARMACEUTICALS, INC.
Carlsbad Research Center
2292 Faraday Avenue
Carlsbad, CA 92008

DOCKET NO.: RTS-0339



Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. RTS-0339	Serial No.
	Applicant Kenneth W. Dobie et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	5,965,790	10/12/1999	Acton	800	18
	AB	6,130,041	10/10/2001	Acton	435	6
	AC	5,962,322	10/5/2001	Kozarsky et al.	435	375
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES NO
	AO	WO 99/11288	3/11/1999	PCT	X
	AP				
	AQ				
	AR				
	AS				
	AT				
	AU				
	AV				
	AW				
	AX				

EXAMINER	DATE CONSIDERED
----------	-----------------

DOCKET NO.: RTS-0339

"Express Mail" Label No.: EV053177089US

Date of Deposit: 12/14/2001

Form PTO-1449 Modified		Docket No. RTS-0339	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Kenneth W. Dobie et al.	
		Filing Date herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Acton et al., Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science, 1996, 271:518-520	
	AB	Acton et al., The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?, Mol. Med. Today, 1999, 5:518-524	
	AC	Acton et al., Expression cloning of SR-BI, a CD36-related class B scavenger receptor, J. Biol. Chem., 1994, 269:21003-21009	
	AD	Buechler et al., Lipopolysaccharide inhibits the expression of the scavenger receptor Cla-1 in human monocytes and macrophages, Biochem. Biophys. Res. Commun., 1999, 262:251-254	
	AE	Calvo et al., The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution, Genomics, 1995, 25:100-106	
	AF	Calvo et al., Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL, J. Lipid Res., 1998, 39:777-788	
	AG	Calvo et al., Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family, J. Biol. Chem., 1993, 268:18929-18935	
	AH	Cao et al., Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1, J. Biol. Chem., 1997, 272:33068-33076	
	AI	Chinetti et al., CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors, Circulation, 2000, 101:2411-2417	
	AJ	Fukasawa et al., SRBI, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells, Exp. Cell Res., 1996, 222:246-250	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. RTS-0339	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Kenneth W. Dobie et al.	
		Filing Date herewith	Group
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AK	Ikemoto et al., Identification of a PDZ-domain-containing protein that interacts with the scavenger receptor class B type I, Proc. Natl. Acad. Sci. U. S. A., 2000, 97:6538-6543	
	AL	Imachi et al., Expression of HDL receptor, CLA-1 in human smooth-muscle cells and effect of interferon-gamma on its regulation, Horm. Metab. Res., 2001, 33:389-393	
	AM	Imachi et al., Human scavenger receptor BI is involved in recognition of apoptotic thymocytes by thymic nurse cells, Lab. Invest., 2000, 80:263-270	
	AN	Krieger, The "best" of cholesterol, the "worst" of cholesterol: a tale of two receptors, Proc. Natl. Acad. Sci. U. S. A., 1998, 95:4077-4080	
	AO	Liu et al., Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells, J. Clin. Endocrinol. Metab., 1997, 82:2522-2527	
	AP	Murao et al., Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes, J. Biol. Chem., 1997, 272:17551-17557	
	AQ	Pussinen et al., The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake, Biochem. J., 2000, 349:559-566	
	AR	Rigotti et al., The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids, The Journal of Biological Chemistry, 1995, 270:16221-16224	
EXAMINER		DATE CONSIDERED	

DOCKET NO.: RTS-0339

JC811 U.S. PTO
 10/024396
 12/18/01

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. RTS-0339	Serial No. not yet assigned
		Applicant Kenneth W. Dobie et al.	
		Filing Date herewith	Group
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Sehayek et al., Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption, <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1998, 95:10194-10199	
	AT	Stangl et al., Transport of lipids from high and low density lipoproteins via scavenger receptor-BI, <i>J. Biol. Chem.</i> , 1999, 274:32692-32698	
	AU	Trigatti et al., Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology, <i>Proc. Natl. Acad. Sci. U. S. A.</i> , 1999, 96:9322-9327	
EXAMINER		DATE CONSIDERED	